<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <fn-group>
  <fn fn-type="COI-statement">
   <p>
    <bold>Conflict of interest:</bold> DMS is Principal Investigator on grants received from the Public Health Agency of Canada in support of this work. GDS has received grants for investigator-initiated studies unrelated to influenza vaccine from Pfizer and provided paid expert testimony for the Ontario Nurses Association, the Quebec Ministry of Justice and GSK. MK has received research grants from Roche, Siemens and Hologic for unrelated studies. Other authors have no conflicts of interest to declare.
   </p>
  </fn>
  <fn fn-type="con">
   <p>
    <bold>Authors’ contributions:</bold> Principal investigator (national and British Columbia): DMS. Co-investigators (epidemiological): JAD (Alberta), MM (Ontario) and GDS (Québec). Co-investigators (laboratory): AJ and MK (British Columbia), MAC (Alberta), JBG (Ontario), HC (Québec) and NB and YL (National Microbiology Laboratory). Additional laboratory and epidemiological support: RO (Ontario). Genomic analyses: SS, DMS. Epidemiological analyses: DMS, SL, CR and MZ. Preparation of first draft: DMS. Draft revision and approval: all.
   </p>
  </fn>
 </fn-group>
</notes>
